Combination Anti-Platelet and Anti-Coagulation Treatment After Lysis of Ischemic Stroke Trial (CATALIST)

NCT00061373 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

18

Enrollment

NIH

Sponsor class

Conditions

Ischemic Stroke

Interventions

DRUG: Aspirin
DRUG: tinzaparin sodium
DRUG: eptifibatide

Sponsor

National Institute of Neurological Disorders and Stroke (NINDS)